Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Clinical trial NCT07032714 · RECRUITING

Trial details

NCT number: NCT07032714
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed Refractory Multiple Myeloma (RRMM)

Start date: 2025-12-19
Primary completion: 2027-07-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.